An interim analysis of NATALEE, a phase III trial evaluating Kisqali (ribociclib) plus endocrine therapy in a broad population of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer at risk of recurrence demonstrated positive topline results.
The breast tumors of Asian, Black and white patients have very different cellular, microbial, and genomic features that could potentially be used to personalize care or predict disease progression, according to research by investigators at the Johns Hopkins Kimmel Cancer Center.Â
Claire L. Streibert was named site chief of breast imaging at Fox Chase Cancer Center and Temple Health.
NCI Director Monica Bertagnolli remembers when Betty Ford and Nancy Reagan went public with their breast cancer diagnoses—and the profound impact those decisions had on oncology.
Research from the University of Wisconsin indicates that for patients with breast cancer, the cancer’s stage and receptor status can help clinicians predict whether and when cancer might recur after initial treatment.Â
Despite racial and ethnic minority groups making up nearly half of the United States population, underrepresentation in clinical trials remains a critical challenge. In an effort to improve clinical trial diversity, researchers at The Ohio State University Wexner Medical Center and College of Medicine partnered with The African American Male Wellness Agency, Genentech Inc., and Pfizer, Inc. to engage with almost 450 community members in 25 states and five countries to create solutions to barriers of access, awareness, discrimination and racism, and workforce diversity.
FDA has approved an expanded indication for Eli Lilly and Company’s Verzenio (abemaciclib), in combination with endocrine therapy, for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer at a high risk of recurrence.
FDA published updates to the mammography regulations to, among other things, require mammography facilities to notify patients about the density of their breasts, strengthen the FDA’s oversight and enforcement of facilities and help interpreting physicians better categorize and assess mammograms.
Breast cancer history is closely tied with the treatment of the most prominent non-elected political person in the country, the First Lady.
The updated National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-Breast Cancer Version 1.2023 recognize Agendia Inc.’s MammaPrint UltraLow Risk result and its proven impact on patient care.
